45 completed, 28 unknown, 22 terminated, 17 withdrawn. 123 Phase 3, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 123 | Completed 45, Unknown 28, Terminated 22, Withdrawn 17, Recruiting 7, Not yet recruiting 2, Suspended 2 |
| Phase 2 | 28 | Unknown 13, Terminated 5, Completed 4, Withdrawn 3, Recruiting 2, Suspended 1 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid - Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 474 | 2025-07-01 | 2025-07-11 |
| Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease Hydroxychloroquine, Placebo - Systemic Lupus Erythematosus | Phase 3 | Recruiting | NYU Langone Health | 330 | 2024-06-27 | 2026-08-20 |
| Tacrolimus for Thrombocytopenia in SS Hydroxychloroquine, Tacrolimus - Sjogren Syndrome With Other Organ Involvement | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 54 | 2023-02-01 | 2023-01-10 |
| Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis Hydroxychloroquine, Colchicine - Pericarditis Idiopathic Recurrent | Phase 3 | Unknown | Hippocration General Hospital | 30 | 2023-02-01 | 2023-02-22 |
| The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia Hydroxychloroquine - Preeclampsia | Phase 3 | Recruiting | Yoo-min Kim | 58 | 2022-05-31 | 2026-09-01 |
| Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Hydroxychloroquine + low-dose prednisone, Prednisone - Pulmonary Sarcoidosis | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 200 | 2022-03-01 | 2022-02-21 |
| #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 Hydroxychloroquine, Mannitol - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | 2022-01-01 | 2025-01-07 | |
| The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy Hydroxychloroquine, Prednisolone - Inflammatory Cardiomyopathy, Myocarditis | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 200 | 2021-11-01 | 2024-10-09 |
| Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Hydroxychloroquine - Mastocytosis | Phase 2 / Phase 3 | Unknown | University Hospital, Toulouse | 30 | 2021-10-01 | 2021-10-20 |
| Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Hydroxychloroquine (HCQ), Standard care, Placebo - Covid19, COVID-19 Prevention | Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1000 | 2021-03-22 | 2021-06-11 |
| Azithromycin Plus Hydroxychloroquine for COVID-19 Infection Azithromycin plus hydroxychloroquine - Respiratory Tract Infection Viral | Phase 3 | Withdrawn | Iterum Therapeutics, International Limited | 2021-02-08 | 2021-10-28 | |
| The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial) Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Placebo - Covid19 | Phase 2 / Phase 3 | Unknown | Corpometria Institute | 294 | 2021-01-25 | 2021-01-15 |
| Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19 Hydroxychloroquine with Azithromycin - Covid19 | Phase 2 / Phase 3 | Unknown | Coordinación de Investigación en Salud, Mexico | 105 | 2021-01-20 | 2021-08-04 |
| The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial Hydroxychloroquine plus standard preventive measures, Placebo plus standard preventive measures - COVID-19 | Phase 3 | Withdrawn | University of the Philippines | 2020-12-01 | 2020-11-06 | |
| Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment Hydroxychloroquine, Favipiravir, Favipiravir + Hydroxychloroquine - Covid19 | Phase 3 | Completed | Health Institutes of Turkey | 1120 | 2020-11-16 | 2021-07-29 |
| Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis hydroxychloroquine - SARS-CoV Infection | Phase 2 / Phase 3 | Unknown | Regional Center for Disease Control and Prevention, Jordan | 93 | 2020-10-27 | 2020-10-22 |
| Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients Hydroxychloroquine + Metabolic cofactor supplementation, Hydroxychloroquine + Sorbitol - COVID-19 | Phase 2 / Phase 3 | Terminated | ScandiBio Therapeutics AB | 100 | 2020-09-21 | 2025-02-10 |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion Hydroxychloroquine Sulfate 200 MG - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Cambridge University Hospitals NHS Foundation Trust | 2020-09-01 | 2021-03-08 |
Showing 20 of 123. Sign in to see all of them.
COVID-19 (78) · Coronavirus Infections (24) · Severe Acute Respiratory Syndrome (11) · Arthritis, Rheumatoid (10) · Pneumonia (6) · Pneumonia, Viral (5) · Respiratory Distress Syndrome (4) · Community-Acquired Pneumonia (3) · Lung Diseases (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Antiphospholipid Syndrome (2) · Autoimmune Diseases (2) · Lupus Erythematosus, Systemic (2) · Respiratory Insufficiency (2)
Assistance Publique - Hôpitaux de Paris (5) · Sanofi (4) · Tanta University (3) · Ain Shams University (2) · Barcelona Institute for Global Health (2) · Cairo University (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Medical University of Vienna (2) · National Institute of Respiratory Diseases, Mexico (2) · University Hospital Tuebingen (2) · University Hospital, Angers (2) · University Hospital, Strasbourg, France (2) · University Hospital, Toulouse (2) · University of Minnesota (2) · University of Nebraska (2)
United States (28) · France (16) · Brazil (8) · Canada (7) · Mexico (7) · Spain (7) · India (6) · China (5) · Egypt (5) · Italy (5) · Russia (5) · Turkey (Türkiye) (5) · Australia (4) · Belgium (4) · Czechia (4)
James R O'Dell, MD (2) · Adrian Hernandez, MD (1) · Alberto Pesci (1) · Alejandro Llanos, MD, PhD (1) · Alexandre Biasi, PhD (1) · Andreas Barratt-Due, MD, PhD (1) · Andrew L. Gilman, MD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1)
PMID 34473343, PMID 32492293, PMID 32673060, PMID 33204764, PMID 33394942, PMID 33570583, PMID 34350582, PMID 34519964, PMID 36695483, PMID 37489818, PMID 38104755, PMID 11824975, PMID 15803929, PMID 17925486, PMID 21149333, PMID 21325604, PMID 21503695, PMID 21669298, PMID 21689773, PMID 2334081, PMID 23462431, PMID 24254965, PMID 24470436, PMID 25027140, PMID 26752081, PMID 27366013, PMID 27860410, PMID 27992698, PMID 28326189, PMID 29125901, PMID 29209946, PMID 29244149, PMID 29556418, PMID 30590833, PMID 30649524, PMID 30877216, PMID 30898821, PMID 32109013, PMID 32150748, PMID 32171076, PMID 32267771, PMID 32304640, PMID 32386744, PMID 32391667, PMID 32453485, PMID 32492354, PMID 32493478, PMID 32497319, PMID 32522251, PMID 32616063
2015 (1), 2016 (1), 2017 (1), 2023 (1), R21AR057924 (1)